Nektar Therapeutics to Report Phase 2b Results for Alopecia Areata Treatment Rezpegaldesleukin
核心洞察
Nektar Therapeutics will host a conference call on December 16, 2025, to discuss topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA clinical trial.
The study evaluates rezpegaldesleukin, a first-in-class regulatory T-cell (搜索) proliferator, for treating severe-to-very-severe alopecia areata (搜索) patients.
Rezpegaldesleukin represents a novel therapeutic approach targeting underlying immunological dysfunction in autoimmune diseases (搜索) through regulatory T-cell (搜索) stimulation.
Nektar Therapeutics announced it will host an investor conference call and webcast on December 16, 2025, at 8:00 am ET to review topline results from the 36-week induction treatment period of its ongoing Phase 2b REZOLVE-AA clinical trial. The study evaluates investigational rezpegaldesleukin for treating severe-to-very-severe alopecia areata (搜索).
Novel Regulatory T-Cell Approach
Rezpegaldesleukin (REZPEG, or NKTR-358) represents a first-in-class regulatory T-cell (搜索) (Treg) proliferator designed to address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases (搜索). The drug works by stimulating regulatory T-cells, which play a crucial role in maintaining immune system balance and preventing autoimmune responses.
The clinical-stage biotechnology company is positioning rezpegaldesleukin as its lead product candidate, with the alopecia areata (搜索) trial being one of multiple ongoing studies evaluating the drug's therapeutic potential across different autoimmune conditions.
Comprehensive Clinical Development Program
Beyond the REZOLVE-AA study, Nektar is conducting two Phase 2b clinical trials with rezpegaldesleukin - one in atopic dermatitis (搜索) and the current alopecia areata (搜索) study - along with one Phase 2 clinical trial in Type 1 diabetes mellitus (搜索). This multi-indication approach reflects the company's strategy to leverage the drug's regulatory T-cell (搜索) stimulation mechanism across various autoimmune diseases (搜索).
Broader Pipeline Development
Nektar's pipeline extends beyond rezpegaldesleukin to include several other investigational therapies. The company is developing preclinical bivalent tumor necrosis factor receptor type II (搜索) (TNFR2) antibody and bispecific programs, designated NKTR-0165 and NKTR-0166, as well as NKTR-422, a modified hematopoietic colony stimulating factor (CSF) protein.
Additionally, Nektar is collaborating with various partners to evaluate NKTR-255, an investigational IL-15 receptor (搜索) agonist designed to enhance the immune system's natural cancer (搜索)-fighting capabilities, in several ongoing clinical trials.
Results Presentation Details
The topline results will be provided in a morning press release on December 16, 2025, followed by presentation during the webcast. The event, press release, and presentation slides will be available on the events section of Nektar's website, with a webcast replay accessible for at least 30 days following the event.
The San Francisco-based company focuses specifically on developing treatments that target immunological dysfunction in autoimmune and chronic inflammatory diseases (搜索), positioning itself as a specialized player in the immunology therapeutics space.